<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230704058663N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-08-16</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the effect of exercise during dialysis on blood phosphorus and urea clearance</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the effect of active exercise during dialysis on uremia and hyperphosphatemia in hemodialysis patient</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-08-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>66</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/71104</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Other, Purpose: Supportive, Other design features: The groups participating in the study receive an independent intervention or no intervention (control group), Randomization description: The replacement of samples in the groups will be done in the form of random allocation using the minimization method. Minimization is done using MiniPie software (http://minimpy.sourceforge.net). Considering the fact that the distribution of urea in the body of patients undergoing hemodialysis (distribution volume of urea) depends on the age, gender, height and weight of the patient, therefore the parameters of age, gender, height and weight for the random allocation of samples in the soft Software will be defined. After selecting the samples in an easy way, the research associate will give a unique number to the sample and after entering the defined variables into the software, the application will place the patient in the test or control group. In other words, the information of 66 patients enters the software, the software will place 33 patients in the test group and 33 patients in the control group. If the software puts a patient with a certain age, sex, height and weight in the test group, it tries to put a similar patient in the control group in terms of the mentioned characteristics, and if there is no similar sample in the 66 entered list. Sampling will continue until the desired number of samples is provided in both groups and the samples are homogeneous, Blinding description: It is not possible to be blinded by the researcher and the samples, but blinding will be done by the analyst or statistician.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Condition 1: Hyperphosphatemia. Condition 2: Uremia.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Intervention group: They will perform an exercise program including active range of motion exercises for 2 weeks and then pedaling a stationary bike or a mini bike for 6 weeks during dialysis. The suggested duration of exercise in each session will gradually increase depending on the patient's ability. Exercise intensity is also measured using standard tools. Intervention 2: Control group: receive routine care during dialysis, including control of vital signs, self-care training, care of vascular access, daily visit of a specialist doctor, nutritional advice, daily weighing in each dialysis session.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Information on the main outcome will be shared.

When:
The access period starts 6 months after the results are published

To whom:
The request of all the people who want to access the data will be answered.

Conditions:
In order to use the protocol in the hospital, to implement the protocol in rehabilitation centers, in cases where it has a supportive and therapeutic aspect for the patient, mention the study results in other researches.

Where to obtain:
Respondent: Elham Hasani
Email address: eli.hsni1996@gmail.com

How to obtain:
After receiving the email, it will be answered within 48 hours.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Elham Hasani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>12 Shohada Alley, Shohada St.</address>
        <city>Lordegan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>88916-83915</zip>
        <telephone>+98 38 3444 9589</telephone>
        <email>eli.hsni.1996@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Elham Hasani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>12 Shohada Alley, Shohada St.</address>
        <city>Lordegan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>88916-83915</zip>
        <telephone>+98 38 3444 9589</telephone>
        <email>eli.hsni.1996@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>All dialysis patients who are over 18 years old.
All dialysis patients who have a fixed number of sessions per week and undergo hemodialysis 3 times a week and each session lasts for 4 hours.
All dialysis patients who have undergone hemodialysis for more than 3 months.
All dialysis patients who use a permanent vascular access.
All dialysis patients who are able to perform active range of motion exercises and pedal independently.
All dialysis patients who have the ability to learn exercises and do not have mental disabilities.
All dialysis patients who had stable hemodynamics during hemodialysis sessions in the last 1 month.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>pregnancy.
Patients with symptomatic and severe aortic stenosis
Patients who have a history of lung disease that requires oxygen therapy
Patients who do not have a history of stroke or transient ischemic attacks in the last 3-6 months
Patients who have a history of heart attack and unstable angina in the past 3-6 months.
Patients with a history of ischemic heart disease
Patients who have any disorders in the musculoskeletal system (orthopedic problems, lower limb amputations, etc.) that prevent them from performing the desired sports activities
Patients with uncontrolled blood pressure.
Patients with uncontrolled diabetes.
Patients who have a history of moderate to severe heart failure (class ≥II according to New York Heart Association criteria).
Patients with a history of angina pectoris grade 2-4 according to the criteria of the Canadian Heart and Vascular Association</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N18.5</hc_code>
      <hc_code>N18.5</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Chronic kidney disease, stage 5</hc_keyword>
      <hc_keyword>Chronic kidney disease, stage 5</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>N/A</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Intervention group: They will perform an exercise program including active range of motion exercises for 2 weeks and then pedaling a stationary bike or a mini bike for 6 weeks during dialysis. The suggested duration of exercise in each session will gradually increase depending on the patient's ability. Exercise intensity is also measured using standard tools.</i_keyword>
      <i_keyword>Control group: receive routine care during dialysis, including control of vital signs, self-care training, care of vascular access, daily visit of a specialist doctor, nutritional advice, daily weighing in each dialysis session.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Blood phosphorus level. Timepoint: At the beginning of the study (before the start of the intervention) and 1 and 2 months after the start of the intervention. Method of measurement: Sending the blood sample to the laboratory.</prim_outcome>
      <prim_outcome>Blood urea level. Timepoint: At the beginning of the study (before the start of the intervention) and 1 and 2 months after the start of the intervention. Method of measurement: Sending the blood sample to the laboratory.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Quality of life. Timepoint: mortality. Method of measurement: hospitalization.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-06-26</approval_date>
        <contact_name>Ethics committee of Isfahan University of Medical Sciences</contact_name>
        <contact_address>Hezar Jerib Street, Isfahan University of Medical Sciences, Building No. 3, Faculty of Medicine, Ground Floor, Department of Medical Ethics Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
